Thalidomide therapy in refractory solid tumour patients

被引：18

作者：

Gutheil, J ^{[1
]}

Finucane, D ^{[1
]}

机构：

[1] Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2000年 / 110卷 / 03期

关键词：

thalidomide; end-stage cancer; refractory; myeloma;

D O I：

10.1046/j.1365-2141.2000.02239-11.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：754 / 754

页数：1

共 4 条

[1] Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells [J].

Dixon, SC ;

Kruger, EA ;

Bauer, KS ;

Figg, WD .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 43 (Suppl 1) :S78-S84

[2] Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas [J].

Fine, HA ;

Figg, WD ;

Jaeckle, K ;

Wen, PY ;

Kyritsis, AP ;

Loeffler, JS ;

Levin, VA ;

Black, PM ;

Kaplan, R ;

Pluda, JM ;

Yung, WKA .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :708-715

[3]

Kneller A, 2000, BRIT J HAEMATOL, V108, P391

[4] Antitumor activity of thalidomide in refractory multiple myeloma. [J].

Singhal, S ;

Mehta, J ;

Desikan, R ;

Ayers, D ;

Roberson, P ;

Eddlemon, P ;

Munshi, N ;

Anaissie, E ;

Wilson, C ;

Dhodapkar, M ;

Zeldis, J ;

Barlogie, B ;

Siegel, D ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) :1565-1571

← 1 →